Sitagliptin in lipid nanoparticles calms neuroinflammation in mice, with NLCs ahead of SLNs
- Sitagliptin was packed into solid lipid nanoparticles and nanostructured lipid carriers of about 50 nm, optimised by experimental design.
- SLNs released drug more slowly; in HepG2 cells NLCs were better tolerated at higher concentrations.
- In a mouse neuroinflammation model both formulations improved behaviour and lowered brain TNF-α, with NLCs doing better.
💡 Points Based on the abstract
The claim of enhanced brain delivery rests on a pharmacodynamic readout; without brain and plasma exposure of free versus encapsulated drug, and a Kp,uu, we cannot tell delivery from a formulation effect on dosing. A neuroinflammation model is also far from Alzheimer's pathology. I would want unbound brain exposure and a head-to-head against plain sitagliptin at the same dose.
📄 Paper · ACS Pharmacology & Translational Science ↗ Sitagliptin-Loaded Lipid Nanoparticles: Shuttles for Alzheimer's Disease Treatment